CMRX Chimerix Inc.

3.48
-0.07  -2%
Previous Close 3.55
Open 3.54
52 Week Low 1.19
52 Week High 4.06
Market Cap $217,965,934
Shares 62,633,889
Float 48,632,632
Enterprise Value $151,287,761
Volume 528,724
Av. Daily Volume 409,583
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
DSTAT
Acute lung injury (ALI) in COVID-19
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
DSTAT (CX-01)
Acute Myeloid Leukemia (AML)
Phase 3
Phase 3
Phase 3 trial to be initiated in early 2021.
Oral Brincidofovir
Smallpox
NDA Filing
NDA Filing
Rolling NDA has been completed - noted November 6, 2020.
Oral Brincidofovir - AdAPT Study
Allogeneic hematopoietic stem cell transplant (HCT) recipients with adenovirus (AdV)
Phase 2
Phase 2
Phase 2 trial discontinued - May 9, 2019.
Brincidofovir - SUPPRESS
Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)
Phase 3
Phase 3
Phase 3 endpoints not met December 2015
IV Brincidofovir
Adult allo-HCT recipients with Adenovirus
Phase 2
Phase 2
Phase 2 trial discontinued - May 9, 2019.
Brincidofovir - SURPASS
Cytomegalovirus (CMV) infection
Phase 3
Phase 3
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SUSTAIN
Cytomegalovirus (CMV) infection
Phase 3
Phase 3
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - Advise trial
Adenovirus Infection
Phase 3
Phase 3
Phase 3 interim analysis released May 2016. Final data released February 22, 2017.

Latest News

  1. DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET.

    A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

    About Chimerix

    Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make…

    DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET.

    A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

    About Chimerix

    Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

    DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been developed in alignment with the US Food and Drug Administration (FDA) and site activation is expected in early 2021. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. For further information, please visit the Chimerix website, www.chimerix.com.

    CONTACT:

    Investor Relations:        

    Michelle LaSpaluto

    919 972-7115



    Will O'Connor

    Stern Investor Relations

    212-362-1200



    Media:

    David Schull

    Russo Partners

    858-717-2310

     

    Primary Logo

    View Full Article Hide Full Article
  2. Completed Rolling NDA Submissions for Both BCV Tablet and Suspension Formulations as Medical Countermeasure for Smallpox

    – First Patient Visit for DSTAT Phase 3 AML Study Expected in Early 2021 –

    Company Well Capitalized Through Several Expected Upcoming Milestones

    Conference Call at 8:30 a.m. ET Today –

    DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an operational update.

    "Throughout the third quarter we continued to make significant progress across a number…

    Completed Rolling NDA Submissions for Both BCV Tablet and Suspension Formulations as Medical Countermeasure for Smallpox

    – First Patient Visit for DSTAT Phase 3 AML Study Expected in Early 2021 –

    Company Well Capitalized Through Several Expected Upcoming Milestones

    Conference Call at 8:30 a.m. ET Today –

    DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an operational update.

    "Throughout the third quarter we continued to make significant progress across a number of key initiatives," said Mike Sherman, Chief Executive Officer of Chimerix. "Of particular note was the completion of our rolling submissions to the U.S. Food and Drug Administration (FDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox. This milestone brings us one step closer to the company's first regulatory approval and to securing a potential procurement contract with BARDA to supply the U.S. Strategic National Stockpile (SNS), which we expect to take place around the time of a potential FDA approval. In addition, we expect to be notified of our Prescription Drug User Fee Act (PDUFA) date relating to these submissions before the end of the year."

    "In addition, we expect to initiate our Phase 3 study of DSTAT for the treatment of acute myeloid leukemia (AML) in early 2021. We were particularly encouraged by a recent meta-analysis of 11,151 patients covering 81 separate studies published in the Journal of the American Medical Association Oncology (Short, et al) in which a link was suggested between minimal residual disease (MRD) status and outcomes in patients with AML. Specifically, this large cohort meta-analysis showed that MRD-negative AML patients experience superior disease-free survival and overall survival rates when compared to patients that are MRD-positive (average hazard ratios of 0.37 and 0.36, for overall survival and disease-free survival respectively). The study suggests that evaluation of MRD status in AML patients may allow for an earlier assessment of therapeutic effects and could lead to acceleration in the development of novel AML therapeutics. This meta-analysis underscores the importance of the MRD assessment that we will undertake following the first 80 evaluable patients in our Phase 3 study in order to better interpret the relapse-free survival and overall survival advantages observed with DSTAT in our smaller Phase 2 study."  

    "Due to the complex and rapidly changing landscape of the current pandemic, we cannot predict when we will complete enrollment in our Phase 2 trial of DSTAT in acute lung injury (ALI) in COVID-19 but do anticipate sharing initial topline data in the first quarter of 2021," concluded Mr. Sherman.   

    Recent Highlights

    • Completed the rolling NDA submissions for BCV tablets and for BCV suspension as a medical countermeasure for smallpox
    • Published manuscript in Advances in Therapy, titled "Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19."
    • Presented data in support of the multi-stage modeling and simulation approach used to determine BCV dosing for the treatment of smallpox in humans at the World Health Organization Advisory Committee on Variola Virus Research

    Expected Upcoming Milestones

    • FDA notification during the fourth quarter of 2020 regarding the acceptance of the BCV NDA submissions and assignment of a PDUFA date
    • Initiation of Phase 3 trial of DSTAT in first line AML in early 2021
    • Potential procurement agreement for BCV around the time of FDA decision on smallpox NDA 
    • FDA decision on BCV smallpox NDA in 2021
    • Completion of Phase 2 trial of DSTAT in COVID-19 related ALI in 2021
    • Completion of BCV drug product manufacturing to support potential shipments to the SNS of up to $100 million in 2021

    Third Quarter 2020 Financial Results

    Chimerix reported a net loss of $11.4 million, or $0.18 per basic and diluted share, for the third quarter of 2020. During the same period in 2019, Chimerix recorded a net loss of $73.7 million, or $1.26 per basic and diluted share.

    Revenues for the third quarter of 2020 decreased to $1.6 million, compared to $2.0 million for the same period in 2019.

    Research and development expenses increased to $10.0 million for the third quarter of 2020, compared to $7.5 million for the same period in 2019. The increase was driven by clinical trial expenses associated with the development of DSTAT.

    General and administrative expenses decreased to $3.2 million for the third quarter of 2020, compared to $4.0 million for the same period in 2019.

    Loss from operations was $11.6 million for the third quarter of 2020, compared to a loss from operations of $74.6 million for the same period in 2019, which included $65 million associated with the licensing of DSTAT in that period.

    Chimerix's balance sheet at September 30, 2020 included $87.8 million of capital available to fund operations, no debt, and approximately 62.6 million outstanding shares of common stock.

    Conference Call and Webcast

    Chimerix will host a conference call and live audio webcast to discuss third quarter 2020 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6085937.

    A live audio webcast of the call will also be available on the Investors section of Chimerix's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

    About Chimerix

    Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

    DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been developed in alignment with the US Food and Drug Administration (FDA) and first patient visit is expected in early 2021. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. For further information, please visit the Chimerix website, www.chimerix.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to obtain regulatory approval for BCV; the timing and receipt of a potential procurement contract for BCV in smallpox; and the initiation, progress and results of the Phase 3 clinical trial of DSTAT in AML and the Phase 2/3 clinical trial of DSTAT in ALI associated with COVID-19. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that DSTAT may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that development activities related to DSTAT may not be completed on time or at all; risks that DSTAT may not achieve the endpoints of its clinical trials; risks that Chimerix will not obtain a procurement contract for BCV in smallpox in a timely manner or at all; Chimerix's reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

    CONTACT:

    Investor Relations:        

    Michelle LaSpaluto

    919 972-7115





    Will O'Connor

    Stern Investor Relations

    212-362-1200





    Media:

    David Schull

    Russo Partners

    858-717-2310

     
    CHIMERIX, INC.
    CONSOLIDATED BALANCE SHEETS
    (in thousands, except share and per share data)
    (unaudited)
            
         September 30, December 31,
          2020   2019 
    ASSETS    
    Current assets:    
     Cash and cash equivalents $38,130  $16,901 
     Short-term investments, available-for-sale  49,635   96,574 
     Accounts receivable  378   1,233 
     Prepaid expenses and other current assets  2,100   3,385 
      Total current assets  90,243   118,093 
    Property and equipment, net of accumulated depreciation  291   540 
    Operating lease right-of-use assets  2,943   709 
    Other long-term assets  27   34 
       Total assets $93,504  $119,376 
            
    LIABILITIES AND STOCKHOLDERS' EQUITY    
    Current liabilities:    
     Accounts payable $880  $2,398 
     Accrued liabilities  6,532   6,830 
      Total current liabilities  7,412   9,228 
    Lease-related obligations  2,923   196 
       Total liabilities  10,335   9,424 
            
    Stockholders' equity:    
     Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2020 and  
      December 31, 2019; no shares issued and outstanding as of September 30, 2020 and   
      December 31, 2019;      
     Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2020 and  
      December 31, 2019; 62,629,722 and 61,590,013 shares issued and outstanding as of   
      September 30, 2020 and December 31, 2019, respectively  63   62 
     Additional paid-in capital  783,758   778,693 
     Accumulated other comprehensive gain, net  33   35 
     Accumulated deficit  (700,685)  (668,838)
      Total stockholders' equity  83,169   109,952 
       Total liabilities and stockholders' equity $93,504  $119,376 
            



    CHIMERIX, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (in thousands, except share and per share data)
    (unaudited)
                 
           Three Months Ended September 30, Nine Months Ended September 30,
           2020   2019   2020   2019 
    Revenues:        
     Contract revenue $1,591  $1,958  $4,158  $5,752 
     Licensing revenue  18   -   94   - 
      Total revenues  1,609   1,958   4,252   5,752 
    Operating expenses:        
     Research and development  10,018   7,453   27,545   34,795 
     General and administrative  3,151   4,024   9,466   18,022 
     Acquired in-process research and development  -   65,045   -   65,045 
      Total operating expenses  13,169   76,522   37,011   117,862 
       Loss from operations  (11,560)  (74,564)  (32,759)  (112,110)
    Other income:        
     Interest income and other, net  149   834   912   3,037 
        Net loss  (11,411)  (73,730)  (31,847)  (109,073)
    Other comprehensive loss:        
     Unrealized (loss)/gain on debt investments, net  (97)  (36)  (2)  182 
        Comprehensive loss $(11,508) $(73,766) $(31,849) $(108,891)
    Per share information:        
     Net loss, basic and diluted $(0.18) $(1.26) $(0.51) $(2.04)
     Weighted-average shares outstanding, basic and diluted 62,242,456   58,457,110   62,009,941   53,519,207 
                 

    Primary Logo

    View Full Article Hide Full Article
  3. DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020, and to provide a business overview.

    To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 6085937. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An…

    DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020, and to provide a business overview.

    To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 6085937. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

    About Chimerix

    Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

    DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been agreed to with the US Food and Drug Administration (FDA) and site activation is expected in early 2021. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, www.chimerix.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

    CONTACT:

    Investor Relations:

    Michelle LaSpaluto

    919 972-7115





    Will O'Connor

    Stern Investor Relations

    212-362-1200





    Media:

    David Schull

    Russo Partners

    858-717-2310

    Primary Logo

    View Full Article Hide Full Article
  4. Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed M. Michelle Berrey, M.D., M.P.H. and Annamaria T. Kausz, M.D., M.S. as members of the company's Board of Directors.

    "We are delighted to welcome Drs. Berrey and Kausz to our Board of Directors. Each brings a wealth of expertise in medical and regulatory strategy, drug development, commercialization and corporate financing," said William Golden, Founder, Chairman and CEO of Noveome.

    "Both Drs. Berrey and Kausz are joining Noveome at a crucial time as we continue our work to advance ST266 for the treatment of ophthalmology indications including persistent…

    Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed M. Michelle Berrey, M.D., M.P.H. and Annamaria T. Kausz, M.D., M.S. as members of the company's Board of Directors.

    "We are delighted to welcome Drs. Berrey and Kausz to our Board of Directors. Each brings a wealth of expertise in medical and regulatory strategy, drug development, commercialization and corporate financing," said William Golden, Founder, Chairman and CEO of Noveome.

    "Both Drs. Berrey and Kausz are joining Noveome at a crucial time as we continue our work to advance ST266 for the treatment of ophthalmology indications including persistent corneal epithelial defects, and systemic inflammation including the cytokine storm often seen in COVID-19."

    Dr. Berrey has over 25 years of combined industry and clinical experience. She is a seasoned industry executive with a proven track record in first-in-class therapeutics targeting viral diseases. Currently, Dr. Berrey serves on the Scientific Advisory Board for ViiV/GSK, and is on the Executive Committee and Board of the NC Biotechnology Center. Dr. Berrey was most recently president and CEO at Chimerix (NASDAQ:CMRX) and previously served as Chief Medical Officer at Pharmasset (acquired by Gilead Sciences (NASDAQ: GILD) and Vice President of Clinical Development for Antivirals and Metabolic Diseases at GlaxoSmithKline (NYSE:GSK). Throughout her career she has focused on diseases threatening the most immunocompromised patient populations. Dr. Berrey holds an M.P.H. from Emory University and an M.D. from the Medical College of Georgia.

    "It's exciting to join the Board of a company like Noveome, rooted in novel science that is unlocking the vast potential of a multi-targeted secretome such as ST266," said Dr. Berrey. "I look forward to working together with the Noveome management team as we aim to improve clinical outcomes in a range of complex diseases."

    Dr. Kausz brings 14 years of experience in drug development and regulatory strategy across several disease areas and all phases of development, including post-marketing. She led the successful filing of two new drug approvals in the U.S. and E.U for renal and metabolic indications, and supported their commercial launch in the U.S. Dr. Kausz is currently the Chief Medical Officer of Allena Pharmaceuticals (NASDAQ:ALNA), where she was instrumental in securing agreement with the FDA on an accelerated approval strategy for a novel indication using a novel endpoint, led several clinical trials, and supported financing activities. Dr. Kausz also serves on the Board of Directors for the Kidney Health Initiative (KHI). She previously held various clinical development roles at EMD-Serono, Keryx, Reata, and AMAG. Dr. Kausz has an M.D. from the University of Virginia and an M.S. in Epidemiology with a concentration in Biostatistics from the University of Washington.

    "It is an honor to join the Noveome Board and I look forward to working with leadership on regulatory strategy, evaluation of indication expansion and business development opportunities," said Dr. Kausz. "ST266 has exciting potential to address the challenges of severe inflammatory responses that can occur in a wide range of indications, and I am eager to help advance Noveome's programs."

    About ST266

    ST266 is a cell-free biologic made by culturing a novel population of human amnion-derived cells. Through a proprietary culturing method, these cells produce an array of growth factors and cytokines, known as the secretome, which promote cellular survival and reduce inflammation.

    About Noveome Biotherapeutics, Inc.

    Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has launched a program to test its novel platform biologic, ST266, as a treatment for the severe inflammatory response seen in COVID-19 infection as well as the post-COVID-19 symptoms experienced by many COVID-19 patients. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs). ST266 is also being evaluated in a Phase 1 open label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose to brain and eye. Noveome is currently planning follow-up clinical studies to characterize the efficacy and safety of ST266 further for the treatment of PEDs and a Phase 1 study evaluating the safety of intravenously administered ST266 in COVID-19 patients. For more information, visit www.noveome.com.

    View Full Article Hide Full Article
  5. DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:

    • H.C. Wainwright 22nd Annual Global Investment Conference: Chimerix will present a corporate overview on Monday, September 14 at 1:00 p.m. ET and participate in investor meetings.
    • Cantor Fitzgerald Virtual Healthcare Conference: Management will participate in investor meetings on Wednesday, September 16.

    A live audio webcast of the H.C. Wainwright conference presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com…

    DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:

    • H.C. Wainwright 22nd Annual Global Investment Conference: Chimerix will present a corporate overview on Monday, September 14 at 1:00 p.m. ET and participate in investor meetings.
    • Cantor Fitzgerald Virtual Healthcare Conference: Management will participate in investor meetings on Wednesday, September 16.

    A live audio webcast of the H.C. Wainwright conference presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

    About Chimerix

    Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

    DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications.  DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19.  A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been agreed to with the US Food and Drug Administration (FDA) and site activation is expected in early 2021.  BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, www.chimerix.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

    CONTACT:

    Investor Relations:                            

    Michelle LaSpaluto

    919 972-7115





    Will O'Connor

    Stern Investor Relations

    212-362-1200

    Media:

    David Schull

    Russo Partners

    858-717-2310

     

    Primary Logo

    View Full Article Hide Full Article
View All Chimerix Inc. News